Unwrap.Fund
See how LABU fits your portfolio →
ETF · holdings as filed 2026-04-30

What's inside LABU?

Direxion Daily S&P Biotech Bull 3X Shares
Holdings
154
positions in the fund
Top 10
32%
of fund assets
Expense ratio
—
net, per year
Fund size
$519M
total net assets
Top 15 holdings
1
—DREYFUS GOVERNMENT CASH MANAGE
7.90%
2
—N/A
7.72%
3
—GOLDMAN FINANCIAL
6.66%
4
—GOLDMAN SACHS LIQ ES FD A
1.82%
5
APLSUSDAPELLIS PHARMACEUTICALS INC
1.53%
6
RVMDREVOLUTION MEDICINES INC
1.35%
7
TVTXTRAVERE THERAPEUTICS INC
1.33%
8
ARWRARROWHEAD PHARMACEUTICALS IN
1.18%
9
TWSTTWIST BIOSCIENCE CORP
1.17%
10
SMMTSUMMIT THERAPEUTICS INC
1.15%
11
ALKSALKERMES PLC
1.14%
12
TGTXTG THERAPEUTICS INC
1.13%
13
MDGLMADRIGAL PHARMACEUTICALS INC
1.12%
14
BEAMBEAM THERAPEUTICS INC
1.09%
15
APGEAPOGEE THERAPEUTICS INC
1.04%
Sectors
1Health Care
78%
2Unclassified
27%
3Industrials
1%
4Financials
0%
Geography
1United States
78%
2Unclassified
24%
3Ireland
1%
4Switzerland
1%
5Bermuda
1%
6Virgin Islands, British
0%
7Netherlands
0%
8Germany
0%
Hold LABU alongside other funds? See your combined true holdings, overlap, and blended fees — free, no signup.
Unwrap your portfolio →
Data source: official SEC Form N-PORT filings (as of 2026-04-30); expense ratio from SEC prospectus (risk/return) filings. Fund holdings are disclosed quarterly and may reflect a 60-day reporting delay.
Informational and educational only — not investment advice.